Editor's note: This article is from the Winter 2009 issue of the Sharing Mayo Clinic Newsletter.
Using the measles virus and gene therapy to treat ovarian cancer
Dixie Manley, of Cedar Falls, Iowa, was the first human to receive a reengineered measles virus to target her ovarian cancer. In July 2004, she participated in a Phase I clinical trial, receiving the virus in Mayo’s Clinical Research Unit. One of the goals of the trial was to study dosage safety and timing. Manley received six cycles of medication with very minimal side effects.
“I knew from the beginning that this research might help me a great deal, or it might not help at all, but I felt that if it didn’t help me, it could possibly lead to something that might help other people,” Manley says.